Unlocking the potential of
genomic medicine

News Release

View printer-friendly version << Back
Medgenics Enhances Strategic Advisory Board

Misgav, Israel and London, UK -9 June 2010 - Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, announces  the addition of a highly experienced Pharmaceutical Executive, Mr. Burt Rosen, to its Strategic Advisory Board. As the Company further develops its technology platform, a competency in dealing with the regulatory and reimbursement issues becomes highly desirable.  As a result, the Company has decided to expand its Scientific Advisory Board to include members that possess a wider range of professional and commercial skills that will be required for the Company going forward.


Burt Rosen is a serial entrepreneur with over 20 years' experience. Burt has developed and implemented Federal, State, and Communications strategies for five major pharmaceutical and consumer product companies. Prior to its sale to Johnson & Johnson in 2009 for $1.17B, Burt served on the Board of Directors of Mentor Corporation, an NYSE listed medical device company.  In his current position as Vice President of Federal Government Relations for Purdue Pharmaceuticals, Burt's primary responsibilities include providing strategic advice and leadership to the senior management of that company, and to act as Chairman of its Issues Co-ordinating Team.


Burt has been active in the government relations and communications industries since 1978, and has worked for such high profile companies as SmithKline Beecham (now GlaxoSmithKline), Bristol-Myers Squibb and Novartis. His duties have ranged from developing legislation to identifying potential licensing and strategic opportunities. The Board of Directors of Medgenics believes that the addition of Burt will provide valuable assistance to the Company as it pursues partnering opportunities and seeks regulatory approval, reimbursement from third party payers (government and private) and sourcing of advocacy groups. The Board further believes that he will be a key asset in strategic planning with extensive contacts and many years of experience as a senior executive in the pharmaceutical industry.


Commenting on the appointment, Dr Andrew Pearlman, CEO of Medgenics said: 'We are delighted by this new appointment and believe that Burt's extensive contacts among senior pharmaceutical executives will complement the work of our top team leading our business development programme.  In addition, the regulatory and lobbying expertise among government and patient advocacy groups will be invaluable as we seek to fully commercialise the Medgenics technology.'



For further information, contact:


Medgenics, Inc.

Dr. Andrew L. Pearlman


Phone: +972 4 902 8900


De Facto Communications

Mike Wort

Anna Dunphy


Phone: +44 207 861 3838

Religare Capital Markets (Nomad)

James Pinner

Derek Crowhurst


Phone: +44 207 444 0800



SVS Securities plc (Joint Broker)

Alex Mattey

Ian Callaway


Phone: +44 207 638 5600



Nomura Code Securities (Joint Broker)

Jonathan Senior



Phone: +44 207 776 1219









This information is provided by RNS
The company news service from the London Stock Exchange